help button home button Endocrine Society Molecular Endocrinology ENDO 08 Sessions Library
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Norris, J. D.
Right arrow Articles by McDonnell, D. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Norris, J. D.
Right arrow Articles by McDonnell, D. P.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Molecular Endocrinology 11 (6): 747-754
Copyright © 1997 by The Endocrine Society

Identification of a Third Autonomous Activation Domain within the Human Estrogen Receptor

John D. Norris, Daju Fan, Sandra A. Kerner and Donald P. McDonnell

Department of Pharmacology, Duke University Medical Center, Durham, North Carolina 27710

Using a genetic selection system established in the yeast Saccharomyces cerevisiae, we have isolated, by random mutagenesis of the human estrogen receptor (ER), six mutants that display constitutive transcriptional activity. All of the mutants identified contained single base insertions or deletions leading to frameshift mutations, resulting in receptor truncations within the hormone-binding domain between amino acids (aa) 324–351. Interestingly, an ER mutant (aa 1–282) was transcriptionally inactive in yeast, suggesting that a domain important for transcriptional activity lies between aa 282 and 351 within human ER. Deletions representative of the mutants isolated in the yeast system were created in mammalian expression vectors and examined for transcriptional activity in animal cells to determine the physiological relevance of this domain. Receptors truncated at aa 282 were either weakly active or inactive; however, an ER deletion at aa 351 was approximately 50% as active as wild type ER (induced with estrogen). Furthermore, a chimeric receptor consisting of the DNA binding domain of GAL4 fused to aa 282–351 of the human ER was transcriptionally active on a GAL4 reporter. We conclude, therefore, that an autonomous activation domain (referred to as AF2a), functional in both yeast and mammalian cells, lies between aa 282–351 of the human ER.




This article has been cited by other articles:


Home page
Mol. Endocrinol.Home page
D. Giacomini, M. Paez-Pereda, J. Stalla, G. K. Stalla, and E. Arzt
Molecular Interaction of BMP-4, TGF-{beta}, and Estrogens in Lactotrophs: Impact on the PRL Promoter
Mol. Endocrinol., July 1, 2009; 23(7): 1102 - 1114.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
X. Di, L. Yu, A.B. Moore, L. Castro, X. Zheng, T. Hermon, and D. Dixon
A low concentration of genistein induces estrogen receptor-alpha and insulin-like growth factor-I receptor interactions and proliferation in uterine leiomyoma cells
Hum. Reprod., August 1, 2008; 23(8): 1873 - 1883.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
D. Kressler, M. B. Hock, and A. Kralli
Coactivators PGC-1beta and SRC-1 Interact Functionally to Promote the Agonist Activity of the Selective Estrogen Receptor Modulator Tamoxifen
J. Biol. Chem., September 14, 2007; 282(37): 26897 - 26907.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
A. Howell
Pure oestrogen antagonists for the treatment of advanced breast cancer.
Endocr. Relat. Cancer, September 1, 2006; 13(3): 689 - 706.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
G. Penot, C. Le Peron, Y. Merot, E. Grimaud-Fanouillere, F. Ferriere, N. Boujrad, O. Kah, C. Saligaut, B. Ducouret, R. Metivier, et al.
The Human Estrogen Receptor-{alpha} Isoform hER{alpha}46 Antagonizes the Proliferative Influence of hER{alpha}66 in MCF7 Breast Cancer Cells
Endocrinology, December 1, 2005; 146(12): 5474 - 5484.
[Abstract] [Full Text] [PDF]


Home page
J Mol EndocrinolHome page
Y. Merot, F. Ferriere, E. Debroas, G. Flouriot, D. Duval, and C. Saligaut
Estrogen receptor alpha mediates neuronal differentiation and neuroprotection in PC12 cells: critical role of the A/B domain of the receptor
J. Mol. Endocrinol., October 1, 2005; 35(2): 257 - 267.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
M. H. Herynk and S. A. W. Fuqua
Estrogen Receptor Mutations in Human Disease
Endocr. Rev., December 1, 2004; 25(6): 869 - 898.
[Abstract] [Full Text] [PDF]


Home page
Toxicol SciHome page
S. O. Mueller, S. Simon, K. Chae, M. Metzler, and K. S. Korach
Phytoestrogens and Their Human Metabolites Show Distinct Agonistic and Antagonistic Properties on Estrogen Receptor {alpha} (ER{alpha}) and ER{beta} in Human Cells
Toxicol. Sci., July 1, 2004; 80(1): 14 - 25.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
Y. Merot, R. Metivier, G. Penot, D. Manu, C. Saligaut, F. Gannon, F. Pakdel, O. Kah, and G. Flouriot
The Relative Contribution Exerted by AF-1 and AF-2 Transactivation Functions in Estrogen Receptor {alpha} Transcriptional Activity Depends upon the Differentiation Stage of the Cell
J. Biol. Chem., June 18, 2004; 279(25): 26184 - 26191.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
D. Bentrem, J. E. Fox, S. T. Pearce, H. Liu, S. Pappas, D. Kupfer, J. W. Zapf, and V. C. Jordan
Distinct Molecular Conformations of the Estrogen Receptor {alpha} Complex Exploited by Environmental Estrogens
Cancer Res., November 1, 2003; 63(21): 7490 - 7496.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. O. Mueller, J. M. Hall, D. L. Swope, L. C. Pedersen, and K. S. Korach
Molecular Determinants of the Stereoselectivity of Agonist Activity of Estrogen Receptors (ER) alpha and beta
J. Biol. Chem., March 28, 2003; 278(14): 12255 - 12262.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
M. Desclozeaux, I. N. Krylova, F. Horn, R. J. Fletterick, and H. A. Ingraham
Phosphorylation and Intramolecular Stabilization of the Ligand Binding Domain in the Nuclear Receptor Steroidogenic Factor 1
Mol. Cell. Biol., October 15, 2002; 22(20): 7193 - 7203.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
J. D. Norris, D. Fan, A. Sherk, and D. P. McDonnell
A Negative Coregulator for the Human ER
Mol. Endocrinol., March 1, 2002; 16(3): 459 - 468.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. Warnmark, A. Wikstrom, A. P. H. Wright, J.-A. Gustafsson, and T. Hard
The N-terminal Regions of Estrogen Receptor alpha and beta Are Unstructured in Vitro and Show Different TBP Binding Properties
J. Biol. Chem., November 30, 2001; 276(49): 45939 - 45944.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
R. Metivier, G. Penot, G. Flouriot, and F. Pakdel
Synergism Between ER{alpha} Transactivation Function 1 (AF-1) and AF-2 Mediated by Steroid Receptor Coactivator Protein-1: Requirement for the AF-1 {alpha}-Helical Core and for a Direct Interaction Between the N- and C-Terminal Domains
Mol. Endocrinol., November 1, 2001; 15(11): 1953 - 1970.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
J. Lamb, M. H. Ladha, C. McMahon, R. L. Sutherland, and M. E. Ewen
Regulation of the Functional Interaction between Cyclin D1 and the Estrogen Receptor
Mol. Cell. Biol., December 1, 2000; 20(23): 8667 - 8675.
[Abstract] [Full Text]


Home page
Mol. Endocrinol.Home page
R. Métivier, F. G. Petit, Y. Valotaire, and F. Pakdel
Function of N-Terminal Transactivation Domain of the Estrogen Receptor Requires a Potential {alpha}-Helical Structure and Is Negatively Regulated by the A Domain
Mol. Endocrinol., November 1, 2000; 14(11): 1849 - 1871.
[Abstract] [Full Text]


Home page
Cancer Res.Home page
J. M. Schafer, H. Liu, D. J. Bentrem, J. W. Zapf, and V. C. Jordan
Allosteric Silencing of Activating Function 1 in the 4-Hydroxytamoxifen Estrogen Receptor Complex Is Induced by Substituting Glycine for Aspartate at Amino Acid 351
Cancer Res., September 1, 2000; 60(18): 5097 - 5105.
[Abstract] [Full Text]


Home page
Mol. Cell. Biol.Home page
L. A. Sheldon, C. L. Smith, J. E. Bodwell, A. U. Munck, and G. L. Hager
A Ligand Binding Domain Mutation in the Mouse Glucocorticoid Receptor Functionally Links Chromatin Remodeling and Transcription Initiation
Mol. Cell. Biol., December 1, 1999; 19(12): 8146 - 8157.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
J. F. Couse and K. S. Korach
Estrogen Receptor Null Mice: What Have We Learned and Where Will They Lead Us?
Endocr. Rev., June 1, 1999; 20(3): 358 - 417.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
D. M. Kraichely, J. J. Collins III, R. K. DeLisle, and P. N. MacDonald
The Autonomous Transactivation Domain in Helix H3 of the Vitamin D Receptor Is Required For Transactivation and Coactivator Interaction
J. Biol. Chem., May 14, 1999; 274(20): 14352 - 14358.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
G. A. Peters and S. A. Khan
Estrogen Receptor Domains E and F: Role in Dimerization and Interaction with Coactivator RIP-140
Mol. Endocrinol., February 1, 1999; 13(2): 286 - 296.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
M. V. Govindan and N. Warriar
Reconstitution of the N-terminal Transcription Activation Function of Human Mineralocorticoid Receptor in a Defective Human Glucocorticoid Receptor
J. Biol. Chem., September 18, 1998; 273(38): 24439 - 24447.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
S. S. Chaidarun and J. M. Alexander
A Tumor-Specific Truncated Estrogen Receptor Splice Variant Enhances Estrogen-Stimulated Gene Expression
Mol. Endocrinol., September 1, 1998; 12(9): 1355 - 1366.
[Abstract] [Full Text]


Home page
Mol. Endocrinol.Home page
Y. Tang, R. H. Getzenberg, B. N. Vietmeier, M. R. Stallcup, M. Eggert, R. Renkawitz, and D. B. DeFranco
The DNA-Binding and {tau}2 Transactivation Domains of the Rat Glucocorticoid Receptor Constitute a Nuclear Matrix-Targeting Signal
Mol. Endocrinol., September 1, 1998; 12(9): 1420 - 1431.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
M. Xu, K. D. Dittmar, G. Giannoukos, W. B. Pratt, and S. S. Simons Jr.
Binding of hsp90 to the Glucocorticoid Receptor Requires a Specific 7-Amino Acid Sequence at the Amino Terminus of the Hormone-binding Domain
J. Biol. Chem., May 29, 1998; 273(22): 13918 - 13924.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. D. Norris, D. Fan, M. R. Stallcup, and D. P. McDonnell
Enhancement of Estrogen Receptor Transcriptional Activity by the Coactivator GRIP-1 Highlights the Role of Activation Function 2 in Determining Estrogen Receptor Pharmacology
J. Biol. Chem., March 20, 1998; 273(12): 6679 - 6688.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1997 by The Endocrine Society